Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT03188783
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
- Conditions
- Gram-negative Bacterial Infections
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT03182504
- Locations
- 🇺🇸
Pulmonary Associates Clinical Trials (PACT), Phoenix, Arizona, United States
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT03178851
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇿🇦Cancercare, Port Elizabeth, South Africa
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03178552
- Locations
- 🇵🇪
Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
🇵🇪Instituto Peruano de Oncología y Radioterapia, Lima, Peru
🇵🇪Clinica Ricardo Palma, San Isidro, Peru
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT03174795
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇭🇺Semmelweis University, First Dept of Medicine, Budapest, Hungary
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT03170284
- Locations
- 🇭🇺
Szent Imre Hospital; Dept. of Oncology, Budapest, Hungary
🇭🇺Fejér Megyei Szent György Kórház; Pulmonary Medicine, Szekesfehervar, Hungary
🇭🇺Debrecen Uni Medical School; Dept of Pulmonary Medicine, Debrecen, Hungary
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT03157635
- Locations
- 🇩🇪
Uniklinik RWTH Aachen, Aachen, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Germany
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT03155347
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳Peking University First Hospital, Beijing City, China
🇨🇳The First Affilliated Hospital of Kunming Medical College, Kunming, China
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT03155009
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Hopital Augustin Morvan; Oncologie Thoracique, Brest, France
🇫🇷Hopital Jean Minjoz; Pneumologie, Besancon, France
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT03153163
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai, China